FDA Hands Out Fast-Track Voucher for Kids' Hearing Loss Drug
Published Date: 5/6/2026
Notice
Summary
The FDA just gave Regeneron a special priority review voucher for their new rare pediatric disease treatment, OTARMENI, approved on April 23, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids and adults with severe hearing loss faster. It’s a big win for patients and could save time and money in bringing new treatments to market.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
OTARMENI approved for OTOF hearing loss
You or your child with severe-to-profound sensorineural hearing loss may be eligible for OTARMENI, which the FDA approved on April 23, 2026. The approval covers pediatric and adult patients with any frequency >90 dB HL who have molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in